Core Insights - Syndax Pharmaceuticals Inc. is identified as a promising stock with significant upside potential, with Barclays raising its price target from $22 to $35 while maintaining an Overweight rating [1][3] Financial Performance - In Q3 2025, Syndax reported total revenue of $45.9 million, reflecting a 21% sequential growth driven by two key products: Revvvi Forge and Nick Timbo [2][3] - Nick Timbo experienced a net revenue increase of 27% compared to the previous quarter, with an annualized revenue of approximately $200 million [3] Product Development and Market Position - Revvvi Forge is expanding its addressable market following FDA approval for relapse-refractory NPM1-mutated AML, in addition to its initial indication for KMT2A-rearranged acute leukemia [3] - The inclusion of Revvvi Forge in the NCCN guidelines has further solidified its position in the treatment landscape [3]